Android app on Google Play

Leerink Swann Resumes Arena Pharma (ARNA) at Outperform

February 6, 2013 7:14 AM EST Send to a Friend
Get Alerts ARNA Hot Sheet
Price: $4.02 -4.06%

Rating Summary:
    4 Buy, 9 Hold, 5 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 12 | New: 33
Trade ARNA Now!
Join SI Premium – FREE
Leerink Swann initiates coverage on Arena Pharma (NASDAQ: ARNA) with a Outperform rating and $11-$12 valuation range.

The firm comments, "Our due diligence points to a significant transformation occurring in the obesity space, similar in scope to smoking cessation a decade ago. The result should be a robust market expansion story advanced by: 1) novel more potent drugs; 2) increasing reimbursement; 3) significant sales & marketing efforts, and; 4) more approvals of effective therapies with co-morbid disease benefits. While the VVUS (OP) Qsymia launch has been slow, ARNA/Eisai's Belviq upcoming launch should work synergistically to broaden the market."

For an analyst ratings summary and ratings history on Arena Pharma click here. For more ratings news on Arena Pharma click here.

Shares of Arena Pharma closed at $8.63 yesterday.




You May Also Be Interested In


Related Categories

New Coverage

Add Your Comment